About Us

Who We Are

The ISCT Presidential Task Force (PTF) on the Use of Unproven and/or Unethical Cell and Gene Therapy is composed of prominent experts in the cell and gene therapy field. Their leadership spans academia, industry, and regulation. The Task Force strives to characterize unproven and unethical cell and gene interventions, and promote safe and effective practices worldwide.

Learn more about the Task Force – Click here to view  

 News

April 3 2019

Statement by FDA Commissioner Scott Gottlieb, M.D., and Biologics Center Director Peter Marks, M.D., Ph.D. on FDA’s continued efforts to stop stem cell clinics and manufacturers from marketing unapproved products that put patients at risk, while progressing the agency’s commitment to help advance legitimate stem cell product development under existing agency regulations

March 27 2019

Recent publication co-authored by members of the ISCT Presidential Task Force critically discusses the current status of cell therapies for lung disease:

Translating Basic Research into Safe and Effective Cell-based Treatments for Respiratory Diseases 

March
2019

Japan’s approval of stem-cell treatment for spinal-cord injury concerns scientists – Nature

Japan should put the brakes on stem cell sales – Nature

January 2019

FDA issues press release on reported safety concerns with Genetech, Inc umbilical cord blood-derived products.

’12 People Hospitalized with Infections from Stem Cell Shots’ – The New York Times

‘FDA Cracks Down on Purveyors of Stem Cell Treatments’ – The Scientist

November 2018

ISCT publishes annual report on cell and gene therapy market authorizations

 June 2018

Speakers from ISCT’s 2018 Annual Meeting Presidential Task Force Session on UCTs referenced in The Medicine Maker: Peter Marks, Massimo Dominici

 June 20, 2018

ISCT Presidential Task Force on UCT Committee Members publish in Lancet Respiratory Medicine:  Leigh Turner, Dan Weiss, Laertis Ikonomou

 August 30, 2017

ISCT Response to Aug 28th FDA Statement Concerning Regulatory Oversight of Cellular Therapies

August 28, 2017

US FDA Commissioner Scott Gottlieb, M.D., issues statement on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine

July 7, 2017

Global interest in report co-authored by members of ISCT Presidential Task Force on UCT

December 2, 2016

ISCT Publishes Article in Translational Scientist Concerning the US REGROW Act

October 19, 2016

ISCT Presidential Task Force Publishes Article in Brain Circulation Journal